PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32397282-4	2020	Rapamycin treatment was started either at day 1 or at day 7 of BAPN+AngII challenge, and continued throughout the observational period.	Sirolimus	0-9	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	68-73	
30074157-0	2018	Rapamycin Treatment Attenuates Angiotensin II -induced Abdominal Aortic Aneurysm Formation via VSMC Phenotypic Modulation and Down-regulation of ERK1/2 Activity.	Sirolimus	0-9	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	31-45	
30074157-11	2018	Moreover, rapamycin reversed Ang II -induced VSMCs phenotypic change both in vivo and in vitro.	Sirolimus	10-19	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	29-35	
27254006-6	2016	To test the functional role of brain mTORC1 in mediating the action of Ang II, we examined the consequence of mTORC1 inhibition with rapamycin on Ang II-induced increase in water intake and arterial pressure.	Sirolimus	133-142	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	146-152	
27254006-7	2016	ICV pretreatment with rapamycin blocked ICV Ang II-mediated increases in the frequency, duration, and amount of water intake but did not interfere with the pressor response evoked by Ang II.	Sirolimus	22-31	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	44-50	
26562437-8	2016	Furthermore, in C57 BL/6 mice with Ang II infusion, intraperitoneal administration of Rapa ameliorated Ang II-induced cardiac fibrosis and cardiac dysfunction, while CQ treatment not only exacerbated Ang II-mediated cardiac fibrosis and cardiac dysfunction, but also impaired cardiac function.	Sirolimus	86-90	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	35-41	
26562437-8	2016	Furthermore, in C57 BL/6 mice with Ang II infusion, intraperitoneal administration of Rapa ameliorated Ang II-induced cardiac fibrosis and cardiac dysfunction, while CQ treatment not only exacerbated Ang II-mediated cardiac fibrosis and cardiac dysfunction, but also impaired cardiac function.	Sirolimus	86-90	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	103-109	
26562437-8	2016	Furthermore, in C57 BL/6 mice with Ang II infusion, intraperitoneal administration of Rapa ameliorated Ang II-induced cardiac fibrosis and cardiac dysfunction, while CQ treatment not only exacerbated Ang II-mediated cardiac fibrosis and cardiac dysfunction, but also impaired cardiac function.	Sirolimus	86-90	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	103-109